Trump has claimed his administration will lower insulin costs to a fixed price, citing voluntary agreements with pharmaceutical companies like Novo Nordisk and a new platform called TrumpRx.gov. Price caps on medications work by setting a ceiling on how much patients pay out-of-pocket—either as a fixed amount per prescription, a percentage of the drug’s cost, or a maximum threshold after which the medication becomes free or significantly cheaper. The mechanism is straightforward in theory: when a patient picks up insulin at a pharmacy, they never pay more than the capped price, regardless of what the drug manufacturer charges or what insurance companies negotiated. For example, under the current Medicare program, seniors with diabetes pay no more than $35 per month for covered insulin products, a cap that took effect in 2023 under the Inflation Reduction Act.
The reality of insulin pricing, however, is more complicated than a simple price ceiling. Trump’s announcements in 2026 include an agreement with Novo Nordisk to cap insulin at $35 per month and a platform offering Insulin Lispro for as low as $25 per month using most-favored-nation pricing—the same mechanism used to align U.S. prices with the lowest prices paid in other developed countries. But these claims require careful scrutiny. A similar program during Trump’s first administration in 2020-2021, which capped insulin at $35 per month for some Medicare recipients, reached less than half of eligible beneficiaries, covering only about 800,000 insulin users by 2022.
Table of Contents
- What Exactly Is Trump Claiming About Lower Insulin Costs?
- How Do Price Caps on Prescription Drugs Actually Work?
- What Specific Actions Has the Trump Administration Taken on Insulin Pricing?
- How Does the Current Medicare Insulin Cap Compare to Trump’s Claims?
- What Are the Real Limitations and Downsides of Drug Price Caps?
- Why Did Trump’s Previous Insulin Cap Program Reach So Few People?
- What Questions Remain About Drug Pricing Strategy Going Forward?
- Conclusion
What Exactly Is Trump Claiming About Lower Insulin Costs?
trump‘s administration has made two major announcements about insulin pricing in 2026. In February, the White House launched TrumpRx.gov, an online platform offering Insulin Lispro for as little as $25 per month through most-favored-nation pricing—a strategy that benchmarks U.S. drug prices against the lowest prices paid by patients in other developed nations like Canada, Germany, and Australia. In April 2026, the administration announced an agreement with Novo Nordisk in which the company would provide NovoLog and Tresiba insulin products at a maximum of $35 per month. These announcements come as the Trump administration emphasizes bringing Price caps operate through several distinct mechanisms, each with different implications for patients and the broader healthcare system. The most common is a fixed copayment, where a patient pays a set dollar amount per prescription regardless of the drug’s actual cost—this is the $35-per-month insulin cap used in Medicare and promised in Trump’s agreements. A second mechanism is co-insurance, where patients pay a percentage of the drug’s price, sharing the cost burden with their insurance plan. A third is a ceiling or out-of-pocket maximum, where patients pay the full negotiated price until they reach a spending threshold, after which the medication becomes free or dramatically cheaper. These three approaches can be combined and often are, creating a layered system where different patient populations face different effective costs. The Congressional Budget Office and health economists have documented that price caps reduce overall medication expenditures and can shift financial burden from insurers to patients, thereby reducing what insurance companies spend on drugs. However, this comes with important consequences. Research published by the National Center for Biotechnology Information shows that price caps may reduce unnecessary use of medications but can also discourage patients from using life-sustaining or chronic-condition medications—a critical warning for a disease like diabetes, where insulin is essential for survival. A patient facing lower prices might consistently use their insulin as prescribed, but across a population, price caps can paradoxically lead some people to use medications less frequently or skip doses to stretch their supply, particularly if they’re uninsured or underinsured and using insulin before the cap takes effect. The TrumpRx.gov platform represents a relatively novel approach to pricing: instead of a government-mandated price ceiling, it harnesses most-favored-nation pricing, a strategy where U.S. prices are tied to the lowest prices paid by other developed nations for the same drugs. When launched in February 2026, the platform made Insulin Lispro available for as low as $25 per month, undercutting even Medicare’s $35 cap. This approach theoretically incentivizes pharmaceutical companies to participate voluntarily by offering them a clear market mechanism: lower prices in the U.S. mean access to a massive patient population, which can drive volume and revenue even at reduced margins. The April 2026 agreement with Novo Nordisk, a major insulin manufacturer, capping NovoLog and Tresiba at $35 per month, was framed as evidence that manufacturers are willing to participate in this framework. The mechanics of MFN pricing reveal both its potential and its limitations. By benchmarking U.S. insulin prices against what patients or governments pay in countries like Germany, France, or Australia, the model imports those nations’ purchasing power into the American market. Germany and many other developed nations negotiate drug prices centrally or have reference pricing systems that typically result in lower prices than Americans have historically paid. When a drug manufacturer agrees to sell insulin at $25 per month in the U.S. through TrumpRx.gov, it’s partly because that price is aligned with what it charges in other wealthy nations—a concession that suggests manufacturers have significant pricing flexibility and that American patients have historically overpaid. However, the voluntary nature of these agreements means manufacturers can refuse to participate, and without mandatory enrollment mechanisms, even lower prices may not reach all patients who need them. The Inflation Reduction Act, signed into law in 2022 under the Biden administration, already mandates that all Medicare Part D plans charge no more than $35 per month for covered insulin products. This is a mandatory cap, not a voluntary program. As of 2026, approximately 3.3 million Medicare beneficiaries enrolled in Part D plans have access to this $35 insulin copay cap, representing one of the largest insulin price protections currently in effect. Importantly, the cap applies regardless of the quantity dispensed—whether a patient fills a one-month or three-month supply, the maximum monthly charge remains $35 (meaning a three-month supply costs no more than $105 total). This cap continues to be in effect and has not been eliminated or altered by the Trump administration, meaning it remains foundational to insulin affordability for seniors. Trump’s announcements of a $35 cap and his TrumpRx.gov platform offering $25 insulin create a more complex landscape. The $35 figure already exists as law; it is not a new policy achievement. The $25 price through TrumpRx.gov is lower than the Medicare cap but applies only to patients who access the platform—and early reports suggest awareness and enrollment have been limited. A working-age American without Medicare, with commercial insurance, who faces high deductibles and copayments before any price cap applies, would benefit more from the TrumpRx.gov platform than a Medicare beneficiary already covered by the Inflation Reduction Act’s $35 cap. This distinction matters: the beneficiary population for the newer Trump administration initiatives may not overlap perfectly with those already protected by Medicare’s insulin cap. While price caps reduce what patients pay at the pharmacy, they carry unintended consequences that healthcare economists have extensively documented. A reduction in the price of a life-saving drug can paradoxically reduce its overall use if it shifts the cost burden in ways that discourage appropriate utilization. For insulin-dependent diabetics, this might mean some patients rationing doses or skipping injections to stretch their supply—behavior that can lead to poor blood glucose control, diabetic complications, emergency room visits, and hospitalizations. The National Center for Biotechnology Information research indicates that price caps can increase use of other, often more expensive, healthcare services as patients who economize on medications end up requiring more intensive medical interventions downstream. A patient who skips insulin doses might avoid the pharmacy but end up in an emergency room with diabetic ketoacidosis, which costs far more to treat than insulin ever would. Another limitation is that price caps do not address the underlying reasons drug prices are high in the first place. Insulin’s list price in the United States is roughly two to three times higher than in other developed nations—a difference that reflects marketing costs, intermediary profit margins, patent protections, and the complex web of drug rebates and negotiations between manufacturers, pharmacy benefit managers, and insurers. A price cap addresses the symptom, the out-of-pocket cost patients face, but not the disease, the inflated list price that necessitates caps in the first place. When a price cap is voluntary, as with Trump’s first-term Part D program and the current TrumpRx.gov agreements, manufacturers retain the power to decide whether to participate, and they may simply offer their products to patients with other insurance or in other markets where price controls are weaker. During the 2020-2021 period, the Trump administration’s Part D Senior Savings Model offered a $35 monthly insulin copay cap to Medicare beneficiaries. Unlike the mandatory Inflation Reduction Act cap now in place, this earlier program was voluntary for insurance plans—each Part D plan could decide whether to adopt it. The result was predictable: fewer than half of Part D plans chose to participate. By 2022, the program had reached approximately 800,000 insulin users, a significant number in absolute terms but a small fraction of the potential beneficiary population. Many Medicare beneficiaries either did not know the program existed, were enrolled in plans that did not participate, or were insured through other means that fell outside the Part D structure entirely. This history raises a critical question about Trump’s 2026 claims. The TrumpRx.gov platform and the Novo Nordisk agreement are also structured on a voluntary basis. Patients must actively seek out and enroll in TrumpRx.gov, and that platform depends on continued manufacturer participation and marketing. The experience with the Part D program suggests that voluntary programs, however well-intentioned, often fail to reach the full population in need. A patient with limited health literacy, no internet access, or an insurance plan that actively discourages participation in competing programs might never find TrumpRx.gov. The difference is that TrumpRx.gov offers $25 insulin, a lower price than even the mandatory Medicare cap, so its success might depend less on universal enrollment and more on reaching the working-age uninsured or underinsured population it targets. The proliferation of insulin pricing programs—the mandatory Medicare cap at $35, TrumpRx.gov at $25, and various Novo Nordisk agreements—reflects an ongoing tension in American healthcare policy. Price caps can provide immediate relief to patients and demonstrable political wins, but they do not address systemic issues like the role of pharmacy benefit managers in inflating list prices, the patent protections that prevent generic competition, or the fundamental misalignment between U.S. and international drug prices. As pharmaceutical companies negotiate with the Trump administration to offer lower prices through voluntary programs, they retain the ability to maintain high list prices and high profits in other segments of the market, and they can shift manufacturing or distribution decisions if caps become unprofitable. Looking ahead, the sustainability of these pricing initiatives depends on manufacturer participation and political commitment. If future administrations reverse course or manufacturers withdraw from agreements, patients could find themselves back in a world of high insulin copays despite the precedent set by 2026’s announcements. The most-favored-nation pricing strategy embedded in TrumpRx.gov is itself subject to international trade dynamics and may face pressure if other countries raise their prices or if manufacturers decide the U.S. market is no longer worth serving at international price levels. The real test of any insulin pricing program is not the price offered to early adopters or the most engaged patients, but whether it reaches the people who need it most: those with chaotic lives, limited resources, and the fewest options. Trump’s claims about lowering insulin costs to a fixed price rest on the principle of price caps—mechanisms that limit what patients pay out-of-pocket and have been proven to reduce medication expenditures. His administration’s agreements, particularly with Novo Nordisk and through the TrumpRx.gov platform, offer specific $35 or $25 monthly insulin costs that are real and, in the case of TrumpRx.gov, lower than existing Medicare protections. However, these programs operate in a landscape already populated by the mandatory $35 insulin cap enacted in 2023, which affects 3.3 million Medicare beneficiaries. Trump’s first-term attempt at a voluntary insulin cap reached only 800,000 users because participation was optional, a pattern that may repeat itself with the current voluntary programs. Patients considering these options should understand both the promise and the limitations. Price caps provide real savings but do not address why insulin costs so much in the first place, and voluntary programs often fail to reach their intended beneficiaries. The most reliable protection for insulin costs remains the mandatory Medicare cap of $35 monthly, while working-age Americans should investigate whether TrumpRx.gov or other programs offer better coverage than their current insurance. As ongoing negotiations reshape insulin pricing, the ultimate measure of success will be whether these policies reach people when they need them most, not just those who actively seek them out.
How Do Price Caps on Prescription Drugs Actually Work?
What Specific Actions Has the Trump Administration Taken on Insulin Pricing?
How Does the Current Medicare Insulin Cap Compare to Trump’s Claims?
What Are the Real Limitations and Downsides of Drug Price Caps?
Why Did Trump’s Previous Insulin Cap Program Reach So Few People?
What Questions Remain About Drug Pricing Strategy Going Forward?
Conclusion
You Might Also Like